Skip to main content

Table 1 Characteristics of 3 patients with acquired hemophilia A that underwent TEG-based analyses

From: Use of thromboelastography before the administration of hemostatic agents to safely taper recombinant activated factor VII in acquired hemophilia A: a report of three cases

Case number Age Sex Symptoms Coagulation tests performed at diagnosis Immunosuppressive Inhibitor Outcome
PT-INR APTT (sec) FVIII:C (%) FVIII inhibitor (BU) therapy recurrence
Case 1 82 Female Bullae with bleeding, Nasal hemorrhage 1.09 80 0.7 5.4 PSLa No Alive at 32 M
Case 2 56 Male Left shoulder joint pain, Difficulty walking 0.96 68 1.3 3.2 PSLa, CPAb, Rituximab No Alive at 31 M
Case 3 58 Female Intramuscular hematoma in left leg, Difficulty walking 0.97 94 1.1 5.9 PSLa No Alive at 18 M
  1. The reference ranges for the PT-INR, APTT, and FVIII:C are 0.8-1.2, 25-35 sec, and 60-140%, respectively
  2. The lower limit of detection of the Bethesda assay was 0.1 BU.
  3. TEG Thromboelastography. PT-INR Prothrombin time-international normalized ratio; APTT Activated partial thromboplastin time
  4. FVIII:C Factor VIII coagulant activity, FVIII Factor VIII, BU Bethesda units, M Months
  5. aPSL Prednisolone, bCPA Cyclophosphamide